292 results on '"Pietra, Gabriella"'
Search Results
2. Immune Checkpoint Inhibitors: Anti-NKG2A Antibodies on Board
3. PLX4032 resistance of patient-derived melanoma cells: crucial role of oxidative metabolism
4. HLA-E-Restricted Recognition of Cytomegalovirus-Derived Peptides by Human CD8 + Cytolytic T Lymphocytes
5. Identification of HLA-E-Specific Alloreactive T Lymphocytes: A Cell Subset That Undergoes Preferential Expansion in Mixed Lymphocyte Culture and Displays a Broad Cytolytic Activity against Allogeneic Cells
6. Peptide-specific recognition of human cytomegalovirus strains controls adaptive natural killer cells
7. The roles of different forms of IL-15 in human melanoma progression
8. Isolation, Expansion, and Characterization of Natural Killer Cells and Their Precursors as a Tool to Study Cancer Immunosurveillance
9. Table S3 from NK-cell Editing Mediates Epithelial-to-Mesenchymal Transition via Phenotypic and Proteomic Changes in Melanoma Cell Lines
10. SI Materials and Methods from NK-cell Editing Mediates Epithelial-to-Mesenchymal Transition via Phenotypic and Proteomic Changes in Melanoma Cell Lines
11. Figures S1-S13 from NK-cell Editing Mediates Epithelial-to-Mesenchymal Transition via Phenotypic and Proteomic Changes in Melanoma Cell Lines
12. Supplementary Methods, Table 1, Figure Legends 1-7 from Melanoma Cells Inhibit Natural Killer Cell Function by Modulating the Expression of Activating Receptors and Cytolytic Activity
13. Supplementary Figure 5 from Melanoma Cells Inhibit Natural Killer Cell Function by Modulating the Expression of Activating Receptors and Cytolytic Activity
14. Data from Melanoma Cells Inhibit Natural Killer Cell Function by Modulating the Expression of Activating Receptors and Cytolytic Activity
15. Supplementary Figure 1 from Melanoma Cells Inhibit Natural Killer Cell Function by Modulating the Expression of Activating Receptors and Cytolytic Activity
16. Supplementary Figure 2 from Melanoma Cells Inhibit Natural Killer Cell Function by Modulating the Expression of Activating Receptors and Cytolytic Activity
17. Supplementary Figure 6 from Melanoma Cells Inhibit Natural Killer Cell Function by Modulating the Expression of Activating Receptors and Cytolytic Activity
18. Supplementary Figure 3 from Melanoma Cells Inhibit Natural Killer Cell Function by Modulating the Expression of Activating Receptors and Cytolytic Activity
19. Supplementary Figure 4 from Melanoma Cells Inhibit Natural Killer Cell Function by Modulating the Expression of Activating Receptors and Cytolytic Activity
20. Supplementary Figure 7 from Melanoma Cells Inhibit Natural Killer Cell Function by Modulating the Expression of Activating Receptors and Cytolytic Activity
21. Whole-Exome Sequencing and cfDNA Analysis Uncover Genetic Determinants of Melanoma Therapy Response in a Real-World Setting
22. Immune Checkpoint Blockade: A Strategy to Unleash the Potential of Natural Killer Cells in the Anti-Cancer Therapy
23. Human natural killer cells: news in the therapy of solid tumors and high-risk leukemias
24. Murine models to study human NK cells in human solid tumors.
25. HO-1 Limits the Efficacy of Vemurafenib/PLX4032 in BRAFV600E Mutated Melanoma Cells Adapted to Physiological Normoxia or Hypoxia
26. Melanoma-Associated Fibroblasts Modulate NK Cell Phenotype and Antitumor Cytotoxicity
27. NK cells and ILCs in tumor immunotherapy
28. Natural killer cell receptors regulate responses of HLA-E–restricted T cells
29. HLA-E-restricted recognition of cytomegalovirus-derived peptides by human [CD8.sup.+] cytolytic T lymphocytes
30. HO-1 Limits the Efficacy of Vemurafenib/PLX4032 in BRAF V600E Mutated Melanoma Cells Adapted to Physiological Normoxia or Hypoxia.
31. Adoptive Immunotherapy With Tumor-Infiltrating Lymphocytes and Subcutaneous Recombinant Interleukin-2 Plus Interferon Alfa-2a for Melanoma Patients With Nonresectable Distant Disease: A Phase I/II Pilot Trial
32. Interleukin-15 and cancer: some solved and many unsolved questions
33. TIGIT Blockade and IL15 in Tumor Immunotherapy: Together is Better
34. Targeted Therapies: Friends or Foes for Patient’s NK Cell-Mediated Tumor Immune-Surveillance?
35. Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer
36. Exploiting Human NK Cells in Tumor Therapy
37. Natural killer cells kill human melanoma cells with characteristics of cancer stem cells
38. Peptides with dual binding specificity for HLA-A2 and HLA-E are encoded by alternatively spliced isoforms of the antioxidant enzyme peroxiredoxin 5
39. Human cytolytic T lymphocytes expressing HLA class-I-specific inhibitory receptors
40. Characterization of metabolic and molecular response of a human melanoma cell line resistant to PLX4032
41. Detection of oligoclonal T lymphocytes in lymph nodes draining from advanced non-small-cell lung cancer
42. NK-CTLs, a novel HLA-E-restricted T-cell subset
43. HO‐1 downregulation favors BRAFV600melanoma cell death induced by Vemurafenib/PLX4032 and increases NK recognition
44. L19-IL2 Immunocytokine in Combination with the Anti-Syndecan-1 46F2SIP Antibody Format: A New Targeted Treatment Approach in an Ovarian Carcinoma Model
45. Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation
46. Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab
47. Titolo BOOK Chapter: NK cell effector mechanisms against solid tumors and leukemias and their exploitation in immunotherapy. Cancer Immunotherapy Principles and Practice, edited by Lisa H. Butterfield, PhD, Howard L. Kaufman, MD, FACS, and Francesco M. Marincola, MD, FACS, (Volume Editors)
48. HO‐1 downregulation favors BRAFV600 melanoma cell death induced by Vemurafenib/PLX4032 and increases NK recognition.
49. 3 Evaluation of HO-1 involvement in melanoma resistance to BRAF inhibitor vemurafenib
50. Hypoxia Modifies the Transcriptome of Human NK Cells, Modulates Their Immunoregulatory Profile, and Influences NK Cell Subset Migration
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.